VESANOID Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Vesanoid, and when can generic versions of Vesanoid launch?
Vesanoid is a drug marketed by Cheplapharm and is included in one NDA.
The generic ingredient in VESANOID is tretinoin. There are twenty-six drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the tretinoin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Vesanoid
A generic version of VESANOID was approved as tretinoin by PADAGIS US on December 24th, 1998.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for VESANOID?
- What are the global sales for VESANOID?
- What is Average Wholesale Price for VESANOID?
Summary for VESANOID
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 140 |
| Clinical Trials: | 23 |
| What excipients (inactive ingredients) are in VESANOID? | VESANOID excipients list |
| DailyMed Link: | VESANOID at DailyMed |
Recent Clinical Trials for VESANOID
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Hospital Universitario Dr. Jose E. Gonzalez | Phase 1/Phase 2 |
| Dwight Owen | Phase 1 |
| Ministry of Health, Saudi Arabia | Phase 3 |
Pharmacology for VESANOID
| Drug Class | Retinoid |
US Patents and Regulatory Information for VESANOID
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cheplapharm | VESANOID | tretinoin | CAPSULE;ORAL | 020438-001 | Nov 22, 1995 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
